Merck & Co., Inc. Impairment of Intangible Assets (Excluding Goodwill)
Merck & Co., Inc. (MRK) reported Impairment of Intangible Assets (Excluding Goodwill) of $55.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2026-02-24
- Merck & Co., Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2023-12-31 was $779.00M, a 7.15% decline year-over-year.
- Merck & Co., Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2022-12-31 was $839.00M, a 177.81% increase year-over-year.
- Merck & Co., Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2022-09-30 was $887.00M.
- Merck & Co., Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2021-12-31 was $302.00M.
- Merck & Co., Inc. impairment of intangible assets (excluding goodwill) for fiscal 2025 was $55.00M, a 41.03% increase from fiscal 2024.
- Merck & Co., Inc. impairment of intangible assets (excluding goodwill) for fiscal 2024 was $39.00M, a 95.08% decline from fiscal 2023.
- Merck & Co., Inc. impairment of intangible assets (excluding goodwill) for fiscal 2023 was $792.00M, a 54.72% decline from fiscal 2022.
- Merck & Co., Inc. impairment of intangible assets (excluding goodwill) for fiscal 2022 was $1.75B, a 479.14% increase from fiscal 2021.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $55.00M 10-K · filed 2026-02-24 | |||
| 2024-12-31 | $39.00M 10-K · filed 2026-02-24 | |||
| 2023-12-31 | $779.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $792.00M 10-K · filed 2026-02-24 | ||
| 2023-09-30 | $13.00M 10-Q · filed 2023-11-03 | |||
| 2022-12-31 | $839.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.73B derived: sum of 2 quarters · filed 2025-02-25 | $1.75B 10-K · filed 2025-02-25 | |
| 2022-09-30 | $887.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $910.00M 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | $23.00M 10-Q · filed 2022-08-05 | |||
| 2021-12-31 | $302.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $302.00M derived: sum of 2 quarters · filed 2024-02-26 | $302.00M 10-K · filed 2024-02-26 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-05 | |||
| 2020-09-30 | $15.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $35.00M 10-Q · filed 2021-11-05 | ||
| 2020-06-30 | $20.00M 10-Q · filed 2021-08-09 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $0.00 derived: sum of 2 quarters · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $0.00 10-Q · filed 2018-08-07 | ||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-08 | |||
| 2017-09-30 | $245.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $296.00M derived: sum of 2 quarters · filed 2018-11-06 | $376.00M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $51.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $131.00M 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | $80.00M 10-Q · filed 2018-05-08 | |||
| 2016-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $295.00M derived: sum of 2 quarters · filed 2017-11-07 | $572.00M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $290.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $567.00M 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | $277.00M 10-Q · filed 2017-05-09 | |||
| 2010-09-30 | $189.50M 10-Q · filed 2010-11-08 | $189.50M derived: sum of 2 quarters · filed 2010-11-08 | $216.20M 10-Q · filed 2010-11-08 | |
| 2010-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-06 | $27.00M 10-Q · filed 2010-08-06 | ||
| 2010-03-31 | $27.00M 10-Q · filed 2010-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |